REDI-Dx, a blood-based gene expression test from DxTerity Diagnostics that estimates individual levels of radiation exposure, was named the 2013 Product of the Year at the Non-Conventional Threat Chemical Biological Radiological Nuclear explosion (NCT CBRNe) Asia conference in Kuala Lumpur, Malaysia. The award committee said it recognized the test because “against the background of mass scale incidents like Fukushima, it permits fast analysis and treatment of victims on the basis of low-cost testing.”
In the wake of a nuclear disaster, the REDI-Dx can help responders triage patients by rapidly providing data about their levels of absorbed ionizing radiation. The test uses a blood sample collected by fingerstick or venipuncture to measure the relative expression of a panel of radiation-sensitive genes. According to Ilja Bonsen, founder and managing director of IB Consultancy, an independent defense and security firm specializing in non-conventional threats, REDI-Dx was selected because “it has a clear end-user benefit, economic efficiency and an excellent match between requirements and the offered solution.”
REDI-Dx was developed as part of an ongoing collaboration between DxTerity Diagnostics and Duke University Medical Center, with funding from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).
For more information, visit DxTerity.
